FDA approves pimicotinib for patients facing harmful tumor surgery
Pimicotinib offers some adults a daily pill instead of damaging tumor surgery, but how much benefit has the trial shown?
On November 10, Merck announced FDA approval of PIMJETMI for certain adults with tenosynovial giant cell tumor, citing a 56% tumor response rate versus 3% with placebo.
Merck announced FDA approval of PIMJETMI (pimicotinib), a once-daily oral treatment for adults with symptomatic tenosynovial giant cell tumor when surgery may worsen function or cause severe harm. In the Phase 3 MANEUVER trial, independently assessed tumor response at week 25 was 56% with the medic…
Published
Compiled by Keldura's AI from 1 source · Passes automated grounding review · Editorial accountability: Yuri Z., Founder & Editor · How this works →
Open original · [7] FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor | AFP.com — afp.com
Merck announced FDA approval of PIMJETMI (pimicotinib), a once-daily oral treatment for adults with symptomatic tenosynovial giant cell tumor when surgery may worsen function or cause severe harm. In the Phase 3 MANEUVER trial, independently assessed tumor response at week 25 was 56% with the medicine versus 3% with placebo. [7] Merck also reported statistically significant improvements in movement, physical functioning and pain. [7]
Why it matters: For eligible adults, approval creates a treatment option when removing the tumor could itself cause substantial disability. The 53-percentage-point response difference is accompanied by reported improvements in pain and function—outcomes that affect daily life, not just tumor measurements. [7]
Key insights: The approval is restricted to symptomatic adults whose surgical resection may worsen functional limitation or cause severe morbidity; it is not a blanket indication for every patient with this tumor. [7] | Tumor responses were assessed by a blinded independent review committee, and the week-25 difference versus placebo was statistically significant. [7] | Among patients who responded at 25 weeks, 77% maintained clinical benefit after another 12 months of follow-up, according to Merck. That percentage describes responders, not everyone treated. [7]
Cheatsheet facts: What happened: Merck announced FDA approval of once-daily PIMJETMI for a defined group of adults with symptomatic tenosynovial giant cell tumor. [7] | Background: For the approved patient group, surgically removing the tumor may worsen physical function or cause severe harm; pimicotinib provides an oral systemic treatment option. [7] | Why: At week 25, tumor response was 56% with pimicotinib versus 3% with placebo, alongside reported improvements in pain, movement and physical function. [7] | The catch: The 77% longer-term benefit figure applies only to patients who had responded at week 25, not to all trial participants. [7]